ArticleJTCVS structural and endovascular2025
Use of pulmonary artery flow restrictors in neonates with congenital heart disease: Timing and technical considerations.
Article in JTCVS structural and endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of Modified Microvascular Plugs as a Pulmonary Flow Restrictors in Congenital Heart Disease.Pediatric cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neonates with congenital heart disease often require restriction of pulmonary blood flow while awaiting definitive palliation or repair. Historically, these patients were managed with pulmonary artery banding. Recently, the use of transcatheter-modified Micro Vascular Plugs as pulmonary flow restrictors has presented a promising alternative for these high-risk patients. Methods: We report our experience with transcatheter pulmonary flow restrictors in neonates with congenital heart disease and increased pulmonary blood flow. Outcomes assessed included successful device placement, procedural complications, procedural mortality, late device migration, progression to surgery, and need for pulmonary artery repair at the time of surgical device removal. Results: Between 2023 and 2025, 9 neonates (median age 14 days) with congenital heart disease, pulmonary overcirculation, and other preoperative risk factors received transcatheter pulmonary flow restrictors. Two patients received a third pulmonary flow restrictor as a second procedure. Twenty pulmonary flow restrictors were placed (17 Micro Vascular Plug 7Q and 3 Micro Vascular Plug 9Q devices). All patients survived the procedure. There were 2 early device migrations and no other procedural complications. In 2 patients, late pulmonary flow restrictor migration left a right and left upper lobe artery unprotected, requiring additional pulmonary flow restrictors. Six patients were successfully bridged to surgery (median interval: 29.5 days), and 1 patient had the transcatheter device removed after 2 weeks. At surgery, the removal of pulmonary flow restrictors was uncomplicated, up to 5.5 months postimplantation, and no pulmonary artery repair was required. Conclusions: Transcatheter palliation using pulmonary flow restrictors is a safe and effective strategy for neonates with congenital heart disease and increased pulmonary blood flow. This approach offers a viable alternative to pulmonary artery banding for bridging high-risk patients to definitive surgical repair, including delayed Norwood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.